It's Prime Week! 18% OFF! Use Code PRIME18 *
Temaril-P is used to treat itching and coughing (including kennel cough) in dogs. Temaril-P is a combination antihistamine (trimeprazine) and corticosteroid (prednisolone). Temaril-P is used for the relief of itching regardless of cause. It is also used in the treatment of various cough conditions such as kennel cough, bronchitis and coughs of nonspecific origin. Temaril-P may also be used for purposes other than those listed here.
Temaril-P contains trimeprazine and prednisolone. Trimeprazine is an antihistamine, which helps relieve itching and coughing. Prednisolone is a corticosteroid that reduces inflammation.
Note: Temaril-P may be administered to animals suffering from acute or chronic bacterial infections provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents.
View Temaril-P Drug Facts Sheet.
The same dosage schedule may be followed for both antipruritic and anti-tussive therapy.
Weight | Initial Dosage |
---|---|
Up to 10 lb | 1/2 tablet, twice daily |
11-20 lb | 1 tablet, twice daily |
21-40 lb | 2 tablets, twice daily |
Over 40 lb | 3 tablets, twice daily |
After 4 days, reduce dosage to 1/2 of the initial dose or to an amount just sufficient to maintain remission of symptoms. Individual animal response will vary and dosage should be adjusted until proper response is obtained.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Clinical and experimental data have demon-strated that corticosteroids administered orally or by injection to animals may induce the first stage of parturi-tion if used during the last trimester of pregnancy and may precipitate premature parturition followed by dysto-cia, fetal death, retained placenta, and metritis. Addi-tionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft pal-ate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. If a vasoconstrictor is needed, norepine-phrine should be used in lieu of epinephrine. Pheno-thiazine derivatives may reverse the usual elevating action of epinephrine causing a further lowering of blood pressure.
All the precautions applicable to cortisone and to phenothiazine derivatives apply also to Temaril-P. Possible side effects attributableto corticosteroids include sodium retention and potas-sium loss, negative nitrogen balance, suppressed adrenalcortical function, delayed wound healing, osteoporosis, elevated levels of SGPT and SAP, and vomiting and diar-rhea (occasionally bloody). Cushings syndrome in dogs has been reported in association with prolonged or repeated steroid therapy. Possible increased suscepti-bility to bacterial invasion and/or the exacerbation of preexisting bacterial infection may occur in patients receiving corticosteroids. As noted above, however, this problem can be avoided by concomitant use of appropri-ate anti-infective agents. Possible side effects attribu-table to phenothiazine derivatives include sedation; pro-truding nictitating membrane; blood dyscrasias; intensifi-cation and prolongation of the action of analgesics, sedatives and general anesthetics; and potentiation of organophosphate toxicity and the activity of procaine hydrochloride.
It should be remembered that the premonitory signs of cortisone overdosage, such as sodium retention and edema, may not occur with prednisolone. Therefore, the veterinarians must be alert to detect less obvious side effects, such as blood dyscrasias, polydipsia, and polyuria.
The appearance and severity of side effects are dose related and are minimal at the recommended dosage level. If troublesome side effects are encountered, the dosage of Temaril-P should be reduced and discontin-ued unless the severity of the condition being treated makes its relief paramount.
Prolonged treatment with Temaril-P must be withdrawn gradually. Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug with-drawal. In patients presently receiving or recently with-drawn from systemic steroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations.
Store in a Dry, Cool Place at Temperatures Not Above 25°C (77°F)